Investor Presentation
Acutaas Chemicals Reaffirms 25% FY27 Growth Guidance in Q1 FY27 Investor Presentation
NSE
acutaas
BSE
543349
- Acutaas Chemicals Limited released its Q1 FY27 Investor Presentation, highlighting strong year-on-year growth in revenue and profitability while reaffirming its confidence in delivering 25% revenue growth for FY27 with stable margins.
- The presentation also highlighted continued momentum in its pharmaceutical intermediates business, operational efficiency improvements, and recognition for workplace excellence and sustainable manufacturing practices.
PRICE-SENSITIVE TRIGGER
Event: Acutaas Chemicals submitted its Q1 FY27 Investor Presentation under Regulation 30 of the SEBI (LODR) Regulations, providing investors with updated financial performance, business highlights, and management outlook.Â
Type: Investor Presentation
Impact: Positive
Immediate Effect: The presentation reinforces management’s confidence in sustained business momentum through FY27 while providing investors with greater visibility into operational performance, profitability, and long-term growth strategy.
Metrics:
Financial Metrics:
- Revenue from Operations: ₹329.7 crore (+59.1% YoY, -23.8% QoQ)
- Gross Profit: ₹190.9 crore (+73.0% YoY)
- Gross Margin: 57.9% (vs 53.2% in Q1 FY26)
- EBITDA: ₹113.1 crore (+122.1% YoY, -38.4% QoQ)
- EBITDA Margin: 34.3% (vs 24.6% in Q1 FY26)
- PBT: ₹103.9 crore (+78.9% YoY)
- PAT: ₹75.0 crore (+70.4% YoY, -44.2% QoQ)
- PAT Margin: 22.7% (vs 21.2% in Q1 FY26)
Segment Performance:
- Advance Intermediates: ₹292.7 crore (+76.5% YoY)
- Specialty Chemicals: ₹37.0 crore (-10.6% YoY)
- Total Revenue: ₹329.7 crore (+59.1% YoY)
Highlight:
- Acutaas Chemicals delivered 122.1% YoY growth in EBITDA with EBITDA margin expanding to 34.3%, driven by a better product mix and improved operational efficiencies.
What Happened ?
Acutaas Chemicals showcased a strong start to FY27 in its investor presentation, reporting significant year-on-year growth across revenue, EBITDA, and net profit. The company attributed the performance to continued momentum in its CDMO and core Advanced Intermediates businesses, while improved product mix and operational efficiencies contributed to substantial margin expansion.
Management also reaffirmed its confidence in achieving 25% revenue growth during FY27 while maintaining stable margins. During the quarter, Acutaas earned Great Place to Work® certification and received the Responsible Care certification from the Indian Chemical Council, highlighting its focus on employee engagement, safety, health, and sustainable manufacturing.
key details
Business Performance & Strategic Highlights:
- Revenue from operations increased 59.1% YoY to ₹329.7 crore.
- Advance Intermediates business grew 76.5% YoY, supported by continued momentum in CDMO and core pharmaceutical intermediates.
- Specialty Chemicals revenue declined 10.6% YoY, as growth in Battery Functional Chemicals (BFC) was offset by softer performance in commodity chemicals.
- Gross margin improved to 57.9%, reflecting a stronger product mix.
- EBITDA margin expanded to 34.3%, supported by operational efficiencies.
- PAT margin improved to 22.7%, despite lower other income during the quarter.
- Management reaffirmed its 25% revenue growth guidance for FY27 with stable margins.
- The company received Great Place to Work® certification.
- Acutaas also obtained the Responsible Care certification from the Indian Chemical Council, recognizing its commitment to safety, environmental responsibility, and sustainable growth.Â
Note:
- The investor presentation indicates that Acutaas continues to benefit from its increasing focus on high-value pharmaceutical intermediates and CDMO opportunities.
- While specialty chemicals remained mixed during the quarter, stronger operating efficiency and favorable product mix supported significant improvement in profitability.
Risk Analysis
Summary:
- Despite strong financial performance, sustaining growth through FY27 will depend on continued demand from pharmaceutical customers, recovery in specialty chemicals, and maintenance of operating margins amid changing raw material and global market conditions.
Key Risks:
- Specialty Chemicals revenue declined during the quarter due to weakness in commodity chemicals.
- Sequential revenue and profitability moderated from the exceptionally strong Q4 FY26.
- Future growth depends on continued execution in CDMO and pharmaceutical intermediates.
- Raw material price volatility and global demand conditions could influence margins.
Worst Case:
- Any slowdown in pharmaceutical demand, prolonged weakness in specialty chemicals, or adverse raw material cost movements could impact the company’s ability to achieve its targeted 25% revenue growth while maintaining stable margins.
Risk Level: Medium
Company Commentary
According to Mr. Naresh Patel, Executive Chairman & Managing Director:
- Revenue grew 59.1% YoY due to the company’s agile business model and consistent customer execution.
- CDMO and Advanced Intermediates businesses continue to deliver strong growth.
- Great Place to Work® certification reflects the company’s strong organizational culture.
- Responsible Care certification reinforces its commitment to safety, health, environmental performance, and sustainable growth.
- Management remains confident of achieving 25% revenue growth in FY27 with stable margins.Â
Official Exchange Filing: Acutaas Chemicals Limited
